Strategic Growth Position ACM Global Central Laboratory as a scalable central lab partner for mid-market biotech firms and emerging biopharma with infectious disease and vaccine projects, leveraging its history of supporting COVID-19 vaccine studies and therapeutic testing.

Vaccine & Therapeutics Highlight opportunities to expand services around vaccine trials and infectious disease therapeutics, building on past COVID-19 study support and Smarter Testing offerings to address evolving clinical trial testing needs.

Global Expertise Emphasize the company’s global central lab capabilities and large test menu (over 1,500 tests across pathology, microbiology, flow cytometry, pharmacogenomics) to win multi-site, complex trials that require diverse analytical capabilities.

Acquisition Readiness Leverage the acquisition history (Drugscan) and affiliation with Rochester Regional Health to appeal to potential enterprise buyers or partners seeking integrated lab services with established aquality and strategic fit.

SME Targeting Focus on mid-sized CROs and sponsors with <$1M revenue segments that could benefit from ACM’s cost-effective, high-volume testing approach and flexible service menu, offering scalable testing packages and white-glove client support.